Slow Capital Inc. Decreases Holdings in BioNTech SE (NASDAQ:BNTX)

Slow Capital Inc. lowered its stake in shares of BioNTech SE (NASDAQ:BNTX) by 5.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 48,727 shares of the company’s stock after selling 2,953 shares during the period. BioNTech comprises 0.8% of Slow Capital Inc.’s investment portfolio, making the stock its 28th biggest position. Slow Capital Inc.’s holdings in BioNTech were worth $5,552,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently modified their holdings of the company. Planning Capital Management Corp lifted its position in BioNTech by 45,000.0% during the third quarter. Planning Capital Management Corp now owns 451 shares of the company’s stock worth $54,000 after buying an additional 450 shares in the last quarter. Blue Trust Inc. increased its holdings in BioNTech by 491.1% in the 3rd quarter. Blue Trust Inc. now owns 467 shares of the company’s stock valued at $55,000 after purchasing an additional 388 shares during the last quarter. GAMMA Investing LLC grew its stake in shares of BioNTech by 21.7% in the third quarter. GAMMA Investing LLC now owns 623 shares of the company’s stock valued at $74,000 after buying an additional 111 shares in the last quarter. Clear Harbor Asset Management LLC purchased a new position in shares of BioNTech in the third quarter valued at approximately $210,000. Finally, Probity Advisors Inc. acquired a new position in shares of BioNTech in the third quarter worth $216,000. Institutional investors and hedge funds own 15.52% of the company’s stock.

BioNTech Trading Up 1.4 %

BNTX opened at $119.75 on Tuesday. BioNTech SE has a 12-month low of $76.53 and a 12-month high of $131.49. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.33 and a quick ratio of 7.21. The stock has a market capitalization of $28.71 billion, a PE ratio of -57.02 and a beta of 0.18. The firm’s fifty day moving average price is $116.14 and its 200 day moving average price is $106.29.

BioNTech (NASDAQ:BNTX) last announced its quarterly earnings data on Monday, November 4th. The company reported $0.81 earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.26) by $2.07. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The firm had revenue of $1.24 billion for the quarter, compared to analysts’ expectations of $514.08 million. During the same period last year, the business posted $0.73 earnings per share. The firm’s revenue for the quarter was up 38.9% on a year-over-year basis. As a group, research analysts expect that BioNTech SE will post -3.77 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts recently weighed in on the stock. BMO Capital Markets reaffirmed an “outperform” rating on shares of BioNTech in a report on Monday, December 2nd. Canaccord Genuity Group increased their price objective on BioNTech from $171.00 to $171.44 and gave the company a “buy” rating in a report on Wednesday, November 27th. HC Wainwright restated a “buy” rating and issued a $150.00 price target on shares of BioNTech in a research report on Monday, November 18th. TD Cowen cut their price target on BioNTech from $132.00 to $122.00 and set a “hold” rating for the company in a report on Tuesday, November 5th. Finally, Berenberg Bank began coverage on shares of BioNTech in a research note on Tuesday, November 19th. They set a “buy” rating and a $130.00 price objective for the company. Three research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $142.72.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.